Aktienanalyse wird geladen …
RVTY · NYSE · Diagnostics & Research · USA
151,11 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2,86 Mrd. | 241,2 Mio. | 2,07 $ | 116,6 Mio. | 0,2 Mio · 0,1 % | 6,4 Mio · 5,5 % | 54,8 % | 8,5 % | 4,37 $ | 0,20 $ | 0,28 $ |
| 2024 | 2,76 Mrd. | 270,39 Mio. | 2,20 $ | 122,82 Mio. | 0,3 Mio · 0,2 % | 2,2 Mio · 1,8 % | 55,8 % | 9,8 % | 4,41 $ | 0,31 $ | 0,28 $ |
| 2023 | 2,75 Mrd. | 693,09 Mio. | 5,55 $ | 124,81 Mio. | 0,3 Mio · 0,2 % | 1,9 Mio · 1,5 % | 56 % | 25,2 % | 0,08 $ | 0,33 $ | 0,28 $ |
| 2022 | 3,31 Mrd. | 569,18 Mio. | 4,50 $ | 126,43 Mio. | 0,3 Mio · 0,3 % | — | 60,1 % | 17,2 % | 4,70 $ | 0,41 $ | 0,28 $ |
| 2021 | 3,83 Mrd. | 943,16 Mio. | 8,08 $ | 116,67 Mio. | 0,2 Mio · 0,2 % | — | 63,6 % | 24,6 % | 11,35 $ | 0,25 $ | 0,28 $ |
| 2020 | 3,78 Mrd. | 727,89 Mio. | 6,49 $ | 112,09 Mio. | 0,2 Mio · 0,2 % | — | 55,8 % | 19,2 % | 7,39 $ | 0,24 $ | 0,28 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q3 2026 | 729,69 Mio. | 51,82 Mio. | 0,46 $ | 111,63 Mio. | 7,1 % | 1,62 $ |
| Q2 2026 | 711,12 Mio. | 40,72 Mio. | 0,36 $ | 111,88 Mio. | 5,7 % | 0,85 $ |
| Q4 2025 | 772,06 Mio. | 98,36 Mio. | 0,84 $ | — | 12,7 % | 1,39 $ |
| Q3 2025 | 698,95 Mio. | 46,65 Mio. | 0,40 $ | 115,46 Mio. | 6,7 % | 1,04 $ |
| Q2 2025 | 720,28 Mio. | 53,95 Mio. | 0,46 $ | 117,54 Mio. | 7,5 % | 0,98 $ |
| Q1 2025 | 664,76 Mio. | 42,24 Mio. | 0,35 $ | 120,23 Mio. | 6,4 % | 0,93 $ |
| Q4 2024 | 729,37 Mio. | 94,65 Mio. | 0,81 $ | — | 13 % | 1,28 $ |
| Q3 2024 | 684,05 Mio. | 94,37 Mio. | 0,77 $ | — | 13,8 % | — |
Sector Update: Healthcare
Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test
Revvity Shares Rise on Launch of Child Type 1 Diabetes Screening Test
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
Leerink Partners Adjusts Revvity Price Target to $160 From $145, Maintains Outperform Rating
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest RVTY und jede andere Aktie unbegrenzt.